CEDAR KNOLLS, N.J.,
Dec. 10, 2019 /PRNewswire/
-- MYOS RENS Technology, Inc. ("MYOS" or "the Company")
(NASDAQ: MYOS), an advanced nutrition company and the owner of
Fortetropin®, a proprietary bioactive composition made from
fertilized egg yolk that helps build lean muscle, announced today
that it will launch its longevity business with the
introduction of its Physician Muscle Health
Formula® at the
27th World Congress on Anti-Aging Medicine
(https://www.a4m.com/las-vegas-december-2019.html) in Las Vegas, Nevada from December 13-15, 2019; MYOS will be in
Booth #2090. Considered the largest event in
anti-aging medicine, the World Congress is expected to draw
approximately 4,000 Medical Professionals and 300 Exhibitors from
around the world.
Earlier this year, MYOS announced that in a clinical trial
involving 60-75-year-old men and women, subjects who consumed
Fortetropin on a daily basis experienced an increase of
approximately 15% in the rate of muscle protein synthesis when
compared with subjects who received a macronutrient-matched
placebo. The results from this clinical trial will be
presented by its principal investigator, William J. Evans, Ph.D., Adjunct Professor of
Nutrition, University of California,
Berkeley at the International Conference on Frailty &
Sarcopenia Research on March 11,
2020 in Toulouse, France.
Encouraged by positive results from this clinical study and
previous studies showing that Fortetropin increases muscle mass and
strength, MYOS decided to formally launch its longevity business by
introducing its branded product, Physician Muscle Health
Formula®. This product will be distributed
through medical practices focused on anti-aging medicine across the
United States. In addition, the Company will also debut a
private labeling service. This service will
enable physicians to develop their own Fortetropin-based nutrition
products in consultation with the Company's scientists and
engineers, leveraging our portfolio of scientific research and
clinical trials. Members of MYOS' scientific and business
development staff will be at the Company's booth (#2090) to
meet with medical professionals and discuss opportunities for
collaboration.
"Fortetropin has remarkable potential to improve human longevity
and we are pleased to share our advancements on improving muscle
health at the upcoming World Congress on Anti-Aging Medicine later
this week," commented Joseph
Mannello, CEO of MYOS. "Maintaining muscle mass and
health plays a vital role in supporting an excellent quality of
life as we get older and has been shown in numerous respected
publications to be associated with improved longevity. Muscle
plays a central role in movement, energy metabolism and bone
health. The beauty of MYOS' approach to addressing muscle
health is that our products are all-natural nutrition products that
capitalize on a patented manufacturing process and are backed by a
large body of preclinical and human clinical research," added Mr.
Mannello.
About MYOS RENS Technology Inc.
MYOS RENS Technology
Inc. (MYOS), "The Muscle Company®", is a Cedar Knolls, NJ-based advanced nutrition
company that develops and markets products that improve muscle
health and performance. MYOS is the owner of
Fortetropin®, a fertilized egg yolk-based product
manufactured via a proprietary process to retain and optimize its
biological activity. Fortetropin has been clinically shown to
increase muscle size, lean body mass and reduce muscle atrophy.
MYOS believes Fortetropin has the potential to redefine existing
standards of physical health and wellness. For more information,
please visit www.myosrens.com.
About Fortetropin®
Fortetropin works in
conjunction with your protein of choice to help your body utilize
that protein more efficiently. Fortetropin is made through a
patented process that maintains the vital nutrients of fertilized
egg yolks to help build more lean muscle and decrease muscle
loss. For more information, please visit
www.myosrens.com.
Forward-Looking Statements
Any statements
in this release that are not historical facts are forward-looking
statements. Actual results may differ materially from those
projected or implied in any forward-looking statements. Such
statements involve risks and uncertainties, including but not
limited to those relating to product and customer demand, market
acceptance of our products, the ability to create new products
through research and development, the successful results of
strategic initiatives, the success of our products,
including Qurr®, Yolked®,
MYOS Canine Muscle Formula®, Physician Muscle Health
Formula® and MYOS Enteral
Nutrition Formula™, the success of our research and
development, the results of the clinical evaluation
of Fortetropin® and its effects, the ability to
enter into new partnership opportunities and the success of our
existing partnerships, the ability to generate revenue and cash
flow from sales of our products, the ability to increase our
revenue and gross profit margins, the ability to achieve a
sustainable, profitable business, the effect of economic
conditions, the ability to protect our intellectual property
rights, competition from other providers and products, the
continued listing of our securities on the Nasdaq Stock Market,
risks in product development, our ability to raise capital to fund
continuing operations, and other factors discussed from time to
time in our filings with the Securities and Exchange
Commission. We undertake no obligation to update or revise any
forward-looking statement for events or circumstances after the
date on which such statement is made except as required by
law.
Investor Relations:
Porter
LeVay & Rose
Matthew Abenante, IRC, SVP
Phone: 212-564-4700
Email: MYOS@plrinvest.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/myos-to-introduce-its-longevity-business-with-its-physician-muscle-health-formula-at-the-world-congress-on-anti-aging-medicine-in-las-vegas-december-13-15-2019-300971732.html
SOURCE MYOS RENS Technology